002019 亿帆医药
已收盘 10-27 15:00:00
资讯
新帖
简况
股市必读：亿帆医药三季报 - 第三季度单季净利润同比增长9.29%
证券之星 · 10-26 07:30
股市必读：亿帆医药三季报 - 第三季度单季净利润同比增长9.29%
亿帆医药（002019）2026年三季报简析：净利润同比下降23.42%
证券之星 · 10-25 06:06
亿帆医药（002019）2026年三季报简析：净利润同比下降23.42%
亿帆医药(002019)9月30日股东户数5.05万户，较上期增加2.01%
证券之星 · 10-24
亿帆医药(002019)9月30日股东户数5.05万户，较上期增加2.01%
图解亿帆医药三季报：第三季度单季净利润同比增长9.29%
证券之星 · 10-24
图解亿帆医药三季报：第三季度单季净利润同比增长9.29%
亿帆医药（002019）披露2026年第三季度报告及前三季度计提资产减值准备议案，10月23日股价上涨1.74%
证券之星 · 10-23
亿帆医药（002019）披露2026年第三季度报告及前三季度计提资产减值准备议案，10月23日股价上涨1.74%
亿帆医药引入卫材原研药海乐卫 肿瘤商业化平台持续扩容
中金财经 · 10-23
亿帆医药引入卫材原研药海乐卫 肿瘤商业化平台持续扩容
亿帆医药(002019)9月30日股东户数5.05万户，较上期增加2.01%
证券之星 · 10-19
亿帆医药(002019)9月30日股东户数5.05万户，较上期增加2.01%
亿帆医药：截止2026年9月10日和9月18日公司股东人数分别为49,450人和49,461人
证券之星 · 10-19
亿帆医药：截止2026年9月10日和9月18日公司股东人数分别为49,450人和49,461人
股市必读：亿帆医药新发布《关于回购公司股份的进展公告》
证券之星 · 10-12
股市必读：亿帆医药新发布《关于回购公司股份的进展公告》
股市必读：亿帆医药新发布《关于回购公司股份的进展公告》
证券之星 · 10-09
股市必读：亿帆医药新发布《关于回购公司股份的进展公告》
亿帆医药（002019）9月29日主力资金净卖出372.14万元
证券之星 · 09-30
亿帆医药（002019）9月29日主力资金净卖出372.14万元
股市必读：亿帆医药新发布《关于与专业投资机构共同投资的进展公告》
证券之星 · 09-30
股市必读：亿帆医药新发布《关于与专业投资机构共同投资的进展公告》
亿帆医药（002019）披露与专业投资机构共同投资进展公告，9月28日股价上涨0.21%
证券之星 · 09-28
亿帆医药（002019）披露与专业投资机构共同投资进展公告，9月28日股价上涨0.21%
亿帆医药：预计下半年将会向泰国市场发货
证券之星 · 09-24
亿帆医药：预计下半年将会向泰国市场发货
亿帆医药：今年下半年亿立舒已在黑山、阿联酋、科索沃获批上市
证券之星 · 09-24
亿帆医药：今年下半年亿立舒已在黑山、阿联酋、科索沃获批上市
亿帆医药：公司对有利于F-652项目开发及商业化的合作机会持开放态度
证券之星 · 09-24
亿帆医药：公司对有利于F-652项目开发及商业化的合作机会持开放态度
亿帆医药：目前境内新增生产场地尚在审评中
证券之星 · 09-24
亿帆医药：目前境内新增生产场地尚在审评中
亿帆医药：非肌层浸润性膀胱癌适应症暂无今年开展临床研究的计划
证券之星 · 09-24
亿帆医药：非肌层浸润性膀胱癌适应症暂无今年开展临床研究的计划
亿帆医药（002019）披露为全资子公司提供1亿元担保进展，9月23日股价下跌0.42%
证券之星 · 09-23
亿帆医药（002019）披露为全资子公司提供1亿元担保进展，9月23日股价下跌0.42%
公司问答丨亿帆医药：公司胰岛素在研项目实施地点在波兰 前期受旅行限制影响 整体研发进度确实与预期存在一些偏差
格隆汇 · 09-14
公司问答丨亿帆医药：公司胰岛素在研项目实施地点在波兰 前期受旅行限制影响 整体研发进度确实与预期存在一些偏差
加载更多
公司概况
公司名称：
亿帆医药股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-13
主营业务：
亿帆医药股份有限公司的主营业务是医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。公司的主要产品是医药自有产品（含进口）、医药其他产品、医药服务、维生素、高分子材料。
发行价格：
12.57
{"stockData":{"symbol":"002019","market":"SZ","secType":"STK","nameCN":"亿帆医药","latestPrice":9.19,"timestamp":1793084634000,"preClose":9.44,"halted":0,"volume":8432959,"delay":0,"changeRate":-0.0265,"floatShares":843000000,"shares":1216000000,"eps":0.2559,"marketStatus":"已收盘","change":-0.25,"latestTime":"10-27 15:00:00","open":9.44,"high":9.52,"low":9.19,"amount":78477500,"amplitude":0.035,"askPrice":9.2,"askSize":249,"bidPrice":9.19,"bidSize":550,"shortable":0,"etf":0,"ttmEps":0.2559,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793151000000},"marketStatusCode":5,"adr":0,"adjPreClose":9.44,"symbolType":"stock","openAndCloseTimeList":[[1793064600000,1793071800000],[1793077200000,1793084400000]],"highLimit":10.38,"lowLimit":8.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1216390085,"isCdr":false,"pbRate":1.29,"roa":"--","peRate":35.912466,"roe":"3.32%","epsLYR":0.33,"committee":0.089955,"marketValue":11179000000,"turnoverRate":0.01,"status":1,"floatMarketCap":7743000000},"requestUrl":"/m/hq/s/002019","defaultTab":"news","newsList":[{"id":"2678349171","title":"股市必读：亿帆医药三季报 - 第三季度单季净利润同比增长9.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678349171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678349171?lang=zh_cn&edition=full","pubTime":"2026-10-26 07:30","pubTimestamp":1792971031,"startTime":"0","endTime":"0","summary":"公司公告汇总：亿帆医药于10月23日召开董事会，审议通过2026年第三季度报告及前三季度计提资产减值准备4413.99万元的议案。业绩披露要点财务报告2026年前三季度主营收入37.22亿元，同比下降5.13%；归母净利润2.97亿元，同比下降23.42%；扣非净利润2.92亿元，同比下降7.33%。公司公告汇总2026年三季度报告2026年第三季度营业收入1,253,952,477.38元，同比下降2.61%；归属于上市公司股东的净利润91,953,389.01元，同比增长9.29%。基本每股收益0.2441元，同比下降23.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600001902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678185177","title":"亿帆医药（002019）2026年三季报简析：净利润同比下降23.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678185177","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678185177?lang=zh_cn&edition=full","pubTime":"2026-10-25 06:06","pubTimestamp":1792879614,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亿帆医药发布2026年三季报。根据财报显示，亿帆医药净利润同比下降23.42%。截至本报告期末，公司营业总收入37.22亿元，同比下降5.13%，归母净利润2.97亿元，同比下降23.42%。按单季度数据看，第三季度营业总收入12.54亿元，同比下降2.61%，第三季度归母净利润9195.34万元，同比上升9.29%。去年的净利率为7.28%，算上全部成本后，公司产品或服务的附加值一般。本文数据来源于亿帆医药2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500000481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677789904","title":"亿帆医药(002019)9月30日股东户数5.05万户，较上期增加2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677789904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677789904?lang=zh_cn&edition=full","pubTime":"2026-10-24 17:09","pubTimestamp":1792832979,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亿帆医药披露，截至2026年9月30日公司股东户数为5.05万户，较9月18日增加993.0户，增幅为2.01%。在化学制药行业个股中，亿帆医药股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年9月18日至2026年9月30日，亿帆医药区间涨幅为0.53%，在此期间股东户数增加993.0户，增幅为2.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400014077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","BK0185","BK0070","BK0197","002019","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677979099","title":"图解亿帆医药三季报：第三季度单季净利润同比增长9.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677979099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677979099?lang=zh_cn&edition=full","pubTime":"2026-10-24 01:17","pubTimestamp":1792775824,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药2026年三季报显示，前三季度公司主营收入37.22亿元，同比下降5.13%；归母净利润2.97亿元，同比下降23.42%；扣非净利润2.92亿元，同比下降7.33%；其中2026年第三季度，公司单季度主营收入12.54亿元，同比下降2.61%；单季度归母净利润9195.34万元，同比上升9.29%；单季度扣非净利润8932.0万元，同比上升14.24%；负债率34.02%，投资收益-2522.87万元，财务费用5904.84万元，毛利率47.32%。财报数据概要请见下图:本文数据来源于亿帆医药2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400002225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677975353","title":"亿帆医药（002019）披露2026年第三季度报告及前三季度计提资产减值准备议案，10月23日股价上涨1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677975353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677975353?lang=zh_cn&edition=full","pubTime":"2026-10-23 22:58","pubTimestamp":1792767494,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，亿帆医药报收于9.36元，较前一交易日上涨1.74%，最新总市值为113.85亿元。该股当日开盘9.14元，最高9.39元，最低8.99元，成交额达9677.88万元，换手率为1.25%。近日，亿帆医药股份有限公司召开第九届董事会第八次会议，审议通过《公司2026年第三季度报告》和《关于2026年前三季度计提资产减值准备的议案》。相关议案的财务信息已经审计委员会2026年第六次会议过半数成员同意。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300046320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0077","002019","BK0185","BK0197","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677916664","title":"亿帆医药引入卫材原研药海乐卫 肿瘤商业化平台持续扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2677916664","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677916664?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:43","pubTimestamp":1792719782,"startTime":"0","endTime":"0","summary":"10月21日，亿帆医药宣布，与卫材(苏州)贸易有限公司正式签署合作协议，获得乳腺癌治疗药物海乐卫在中国大陆的进口、销售和推广独家权益。而亿帆医药这套经过多家跨国药企检验的合规体系，恰恰是其肿瘤药商业化平台最坚实的护城河。目前，亿帆医药的肿瘤药产品线早已不是\"单兵作战\"。对亿帆医药而言，海乐卫的加入既是产品矩阵补强，也是公司“自研+引入”商业化平台能力的又一次验证。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202610/23/20261023615016.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202610/23/20261023615016.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20261023/32406063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0070","BK0191","002019","BK0185","BK0077","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676013501","title":"亿帆医药(002019)9月30日股东户数5.05万户，较上期增加2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676013501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676013501?lang=zh_cn&edition=full","pubTime":"2026-10-19 17:23","pubTimestamp":1792401834,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亿帆医药披露，截至2026年9月30日公司股东户数为5.05万户，较9月18日增加993.0户，增幅为2.01%。在化学制药行业个股中，亿帆医药股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.69万户。从股价来看，2026年9月18日至2026年9月30日，亿帆医药区间涨幅为0.53%，在此期间股东户数增加993.0户，增幅为2.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900022110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0191","BK0239","BK0070","BK0185","002019","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676503247","title":"亿帆医药：截止2026年9月10日和9月18日公司股东人数分别为49,450人和49,461人","url":"https://stock-news.laohu8.com/highlight/detail?id=2676503247","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676503247?lang=zh_cn&edition=full","pubTime":"2026-10-19 15:06","pubTimestamp":1792393575,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)10月19日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止9月10日和20日，公司最新股东人数分别是多少？亿帆医药回复：您好，截止2026年9月10日和9月18日公司股东人数（合并普通账户和融资融券信用账户）分别为49,450人和49,461人。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900012891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0191","BK0070","002019","BK0239","BK0185","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674846413","title":"股市必读：亿帆医药新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674846413","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674846413?lang=zh_cn&edition=full","pubTime":"2026-10-12 04:02","pubTimestamp":1791748936,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司于2026年10月9日收到枸橼酸伊沙佐米胶囊上市许可申请《受理通知书》，该药2025年国内销售额8.90亿元，公司累计研发投入约1,762.43万元。公司公告汇总关于回购公司股份的进展公告截至2026年9月30日，公司已回购股份5,000,000股，占总股本的0.41%，成交均价为10.79元/股，成交总金额为5,394.36万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","BK0191","BK0197","BK0185","BK0239","002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674007104","title":"股市必读：亿帆医药新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674007104","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674007104?lang=zh_cn&edition=full","pubTime":"2026-10-09 03:51","pubTimestamp":1791489067,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，亿帆医药报收于9.44元，上涨0.21%，换手率0.92%，成交量7.76万手，成交额7358.37万元。公司公告汇总：截至2026年9月30日，亿帆医药已回购股份5,000,000股，占总股本0.41%，成交总金额5,394.36万元。公司公告汇总关于回购公司股份的进展公告亿帆医药股份有限公司于2026年5月27日和6月12日分别召开董事会及临时股东大会，审议通过回购股份并用于注销的议案。回购进展符合相关法规及公司方案要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900003070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","002019","BK0070","BK0239","BK0197","BK0191","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671226708","title":"亿帆医药（002019）9月29日主力资金净卖出372.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671226708","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671226708?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:16","pubTimestamp":1790731002,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月29日收盘，亿帆医药报收于9.23元，下跌1.6%，换手率0.92%，成交量7.74万手，成交额7193.27万元。近5日资金流向一览见下表：亿帆医药融资融券信息显示，融资方面，当日融资买入780.01万元，融资偿还369.53万元，融资净买入410.48万元。亿帆医药主营业务：医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000007807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","002019","BK0191","BK0197","BK0077","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671241637","title":"股市必读：亿帆医药新发布《关于与专业投资机构共同投资的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671241637","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671241637?lang=zh_cn&edition=full","pubTime":"2026-09-30 01:54","pubTimestamp":1790704455,"startTime":"0","endTime":"0","summary":"公司公告汇总关于与专业投资机构共同投资的进展公告亿帆医药全资子公司合肥欣竹生物科技有限公司作为有限合伙人，以自有资金认缴出资10,000万元参与投资设立天津高榕长赢股权投资基金合伙企业。基金总认缴出资额为326,100万元，共有15名合伙人，其中合肥欣竹生物科技有限公司出资占比3.0665%。其他有限合伙人与公司及公司控股股东、实际控制人等均无关联关系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000002252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0077","BK0239","002019","BK0191","BK0070","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670255865","title":"亿帆医药（002019）披露与专业投资机构共同投资进展公告，9月28日股价上涨0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670255865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670255865?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:24","pubTimestamp":1790605461,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，亿帆医药报收于9.38元，较前一交易日上涨0.21%，最新总市值为114.1亿元。该股当日开盘9.38元，最高9.47元，最低9.33元，成交额达4856.81万元，换手率为0.61%。近日，亿帆医药披露《关于与专业投资机构共同投资的进展公告》。基金总认缴出资额为326,100万元，共有15名合伙人，其中合肥欣竹生物科技有限公司出资占比3.0665%。其他有限合伙人与公司及公司控股股东、实际控制人等均无关联关系。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800035082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0197","BK0191","BK0239","BK0070","BK0185","002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669531456","title":"亿帆医药：预计下半年将会向泰国市场发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2669531456","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669531456?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:36","pubTimestamp":1790220977,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！f627在全球其它未上市国家实现销售会加快吗？预计年末前还会有新增国家实现发货吗？亿帆医药回复：感谢您的关注与提问。海外市场注册与商业化由公司及合作方在积极推进，具体发货国家、时间受注册审批、订单及供应链安排等因素影响。公司正在推进泰国市场发货准备工作，预计下半年将会向泰国市场发货。谢谢！同时，预祝您中秋佳节快乐！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0070","BK0239","002019","BK0191","BK0077","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669456519","title":"亿帆医药：今年下半年亿立舒已在黑山、阿联酋、科索沃获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2669456519","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669456519?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:36","pubTimestamp":1790220977,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司，今年下半年亿立舒还可能在哪里国家正式上市？2027年预计哪些国家可以发货？亿帆医药回复：感谢您的关注与提问。今年下半年截至目前，亿立舒上市申请已经在黑山、阿联酋、科索沃三个国家/地区获批上市。亿立舒海外上市及发货计划受当地注册审批、合作方商业化安排、供应链等多种因素影响。公司将持续推进已布局市场的注册和商业化。谢谢！同时，预祝您中秋佳节快乐！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019","BK0070","BK0197","BK0077","BK0185","BK0239","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669456508","title":"亿帆医药：公司对有利于F-652项目开发及商业化的合作机会持开放态度","url":"https://stock-news.laohu8.com/highlight/detail?id=2669456508","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669456508?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:36","pubTimestamp":1790220977,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：f652在美国已经做II期临床试验了，公司会否考虑在美国找一个合适的合作伙伴BD，共同开发？亿帆医药回复：感谢您的关注与提问。公司对有利于F-652项目开发及商业化的合作机会持开放态度。同时，我们会及时向管理层转达您的建议。谢谢！同时，预祝您中秋佳节快乐！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0070","002019","BK0185","BK0197","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669513456","title":"亿帆医药：目前境内新增生产场地尚在审评中","url":"https://stock-news.laohu8.com/highlight/detail?id=2669513456","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669513456?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:36","pubTimestamp":1790220971,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问 贵公司公告号 2022-053 商业化合作协议之补充协议，已经落实到哪一步了？可否明确回复一下里面里程款付款情况，MAH转移到哪一步了，7200万收到没有？亿帆医药回复：感谢您的关注与提问。（1）相关事项正按协议约定及监管程序推进，目前境内新增生产场地尚在审评中；（2）目前没有收到MAH转移的款项。谢谢！同时，预祝您中秋佳节快乐！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0077","BK0239","BK0191","BK0070","BK0185","002019"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669565114","title":"亿帆医药：非肌层浸润性膀胱癌适应症暂无今年开展临床研究的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2669565114","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669565114?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:36","pubTimestamp":1790220970,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，N-3C01注射液的另一个适应症今年计划推进临床研究吗？谢谢！亿帆医药回复：感谢您的关注与提问。N-3C01各适应症的临床开发计划需结合临床需求、竞争格局及公司资源统筹评估。非肌层浸润性膀胱癌适应症暂无今年开展临床研究的计划。谢谢！同时，预祝您中秋佳节快乐！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0070","002019","BK0185","BK0197","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669484966","title":"亿帆医药（002019）披露为全资子公司提供1亿元担保进展，9月23日股价下跌0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669484966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669484966?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:25","pubTimestamp":1790173517,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘，亿帆医药报收于9.55元，较前一交易日下跌0.42%，最新总市值为116.17亿元。近日，亿帆医药披露《关于为全资子公司提供担保的进展公告》。公告显示，公司于2026年9月22日与交通银行安徽省分行签订《保证合同》，为全资子公司合肥亿帆医药有限公司提供最高额人民币10,000万元的连带责任保证担保，用于其业务发展需要。截至目前，公司及控股子公司累计对外担保余额为49.49亿元，占2025年经审计净资产的56.02%，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300041152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0191","BK0239","BK0185","002019","BK0197","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659066","title":"公司问答丨亿帆医药：公司胰岛素在研项目实施地点在波兰 前期受旅行限制影响 整体研发进度确实与预期存在一些偏差","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659066","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659066?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:45","pubTimestamp":1789375507,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0191","BK0070","BK0077","BK0239","BK0197","002019","BK0185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793123659901,"stockEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0182},{"period":"3month","weight":-0.1025},{"period":"6month","weight":-0.1701},{"period":"1year","weight":-0.2873},{"period":"ytd","weight":-0.2241}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.0471},{"period":"6month","weight":-0.1128},{"period":"1year","weight":-0.0872},{"period":"ytd","weight":-0.0808}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"亿帆医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"50454人(较上一季度增加2.01%)","perCapita":"16698股","listingDate":"2004-07-13","address":"浙江省杭州市临安区临安经济开发区","registeredCapital":"121639万元","survey":" 亿帆医药股份有限公司的主营业务是医药产品、原料药和高分子材料的研发、生产、销售及药品推广服务。公司的主要产品是医药自有产品（含进口）、医药其他产品、医药服务、维生素、高分子材料。","listedPrice":12.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亿帆医药,002019,亿帆医药股票,亿帆医药股票老虎,亿帆医药股票老虎国际,亿帆医药行情,亿帆医药股票行情,亿帆医药股价,亿帆医药股市,亿帆医药股票价格,亿帆医药股票交易,亿帆医药股票购买,亿帆医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亿帆医药(002019)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亿帆医药(002019)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}